Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial
Eli Lilly and Company
1,205 participants
Oct 31, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administered orally
Administered orally
Locations(154)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07223593